In particular, retatrutide, a triple agonist targeting GLP-1 receptors, GIP, and glucagon receptors, has demonstrated substantial metabolic benefits, raising interest in its potential for treating substance use disorders as well (Jastreboff et al
In Australia in 2023, there were approximately 2.5 million prescriptions for Semaglutide alone under the Pharmaceutical Benefits Scheme, which is nearly double the previous years total prescription 12
Clinical Therapeutics , 47 (4), 316329.
Splitting your dose can be a great tool to make your treatment better
The faster you drop weight, the more likely you are to suffer temporary side effects. The landmark study on semaglutide for weight loss mentioned a sustained effectGLP-1 users consistently lose weight for months on end